Browse the evidence

Twelve weeks of dapiglutide (4 mg or 6 mg) once weekly does not produce a statistically significant reduction in body weight compared to placebo in adults with obesity.

In this study, taking 4 mg or 6 mg of dapiglutide once weekly for 12 weeks did not lead to significant weight loss compared to a placebo in people with obesity. The drug was safe, but the dose might be too low or the treatment period too short to see results. Future studies may need higher doses or longer durations.

Emergency department exposures to GLP-1 and GLP-1/GIP receptor agonists predominantly result in mild, self-limiting gastrointestinal symptoms (nausea, vomiting) that typically resolve within 8 to 24 hours with supportive care.

If you or someone else takes too much of a GLP-1 medication (like Ozempic or Wegovy), expect nausea and vomiting. These symptoms are usually mild and go away within a day. Focus on hydration and rest. Seek medical help if you feel faint, have severe abdominal pain, or cannot keep fluids down.

Serum resistin concentrations are not significantly correlated with insulin sensitivity (glucose disposal rate) in obese or obese diabetic humans, indicating resistin is unlikely to be a major mediator of insulin resistance in these populations.

For individuals with obesity or type 2 diabetes, serum resistin levels are not a reliable indicator of insulin sensitivity, nor is lowering resistin likely to be a primary strategy for improving insulin resistance. Focus on established interventions like weight management and physical activity rather than targeting resistin specifically.

Serum resistin levels are directly correlated with resistin mRNA expression in abdominal subcutaneous adipose tissue, suggesting adipose tissue is a source of circulating resistin.

Measuring resistin mRNA in fat biopsies is a valid proxy for estimating serum resistin levels in obese individuals, as they are strongly correlated.

YouTube videos on semaglutide (Ozempic/Wegovy) largely fail to adequately communicate critical safety risks, specifically the risk of aspiration during anesthesia, the persistence of side effects due to the drug's long half-life, the risk of counterfeit drugs, and the lack of long-term data.

Do not rely on YouTube videos for safety information about semaglutide. They often miss critical risks like aspiration during surgery, the persistence of side effects due to the drug's long half-life, and the danger of counterfeit products. Always consult a physician for personalized advice and safety monitoring.

Childhood adversities are associated with an increased risk of fatal or non-fatal CHD events in adulthood.

Early life trauma has long-lasting physical consequences, increasing the risk of heart disease later in life. While you cannot change your childhood, being aware of this risk factor allows for more proactive cardiovascular monitoring and stress management in adulthood.

PPARgamma agonists (thiazolidinediones like rosiglitazone) improve insulin sensitivity in obese models by downregulating macrophage-derived inflammatory gene expression in white adipose tissue.

Drugs that activate PPARgamma (like rosiglitazone) work partly by calming inflammation in fat tissue. This suggests that anti-inflammatory strategies might be a valid adjunct to metabolic health management in obesity.

Exposure to endocrine-disrupting chemicals (EDCs) during critical developmental windows (fetal, neonatal, pubertal) causes long-term reproductive, metabolic, and oncological disorders in adulthood through non-traditional dose-response mechanisms and epigenetic modifications.

Minimize exposure to endocrine disruptors, especially during pregnancy and childhood. Reduce use of plastics containing BPA/phthalates, choose fresh foods over canned/processed when possible, and be aware of environmental contaminants. The risk is cumulative and developmental, so early life protection is critical.

Oral administration of viable Akkermansia muciniphila reverses high-fat diet-induced obesity, metabolic endotoxemia, and insulin resistance in mice by restoring gut barrier function and increasing intestinal endocannabinoids.

This research suggests that consuming live Akkermansia muciniphila, potentially through specific fermented foods or future supplements, may help improve gut health and metabolic function in individuals prone to obesity and insulin resistance. However, current evidence is from animal studies, so human application requires further clinical validation. Focus on a balanced diet rich in prebiotics (like oligofructose) which may naturally support the growth of this beneficial bacterium.

Periodic administration of the senolytic drug combination Dasatinib and Quercetin (D+Q) selectively eliminates senescent cells, thereby extending healthspan and delaying age-related pathologies in murine models.

The research suggests that a specific combination of Dasatinib and Quercetin, taken periodically (weekly) at specific doses, can clear senescent cells and extend healthspan in mice. While promising, this is preclinical data. Humans should not self-administer these drugs without medical supervision, as the long-term safety and optimal dosing for humans are not yet established.

The transcription factor mPPAR gamma 2 (PPAR-gamma 2) functions as a tissue-specific regulator that, when heterodimerized with RXR alpha, activates the adipocyte-specific aP2 enhancer to drive adipocyte differentiation and gene expression.

This paper identifies PPAR-gamma 2 as a master switch for fat cell identity. While it doesn't prescribe a diet, it explains why fat cells are distinct from other cells and how they respond to fatty acids and specific drugs (like thiazolidinediones, implied by 'peroxisome proliferators'). For health, this underscores that fat is biologically active and regulated by specific molecular pathways.

Semaglutide 0.4 mg does not significantly improve liver fibrosis stage compared to placebo in patients with NASH and fibrosis stage F2 or F3.

For patients with NASH and fibrosis stages F2 or F3, treatment with 0.4 mg of subcutaneous semaglutide daily for 72 weeks does not significantly improve liver fibrosis stage compared to placebo, despite improving NASH resolution. This suggests that while semaglutide is effective for resolving NASH, it may not be sufficient for reversing fibrosis in all patients.

Hormone therapy increases the risk of stroke regardless of the time since menopause or the age of the woman.

Regardless of when you start hormone therapy, your risk of stroke increases. This risk is independent of your age or how long it has been since menopause. If you are considering hormone therapy, this increased stroke risk must be weighed against the potential benefits for menopausal symptoms and the potential CHD benefits (if starting early).

An AST/ALT ratio greater than 1 is an independent predictor of severe liver fibrosis (bridging fibrosis or cirrhosis) in NASH patients, independent of age, obesity, and diabetes.

Ask your doctor about your AST/ALT ratio. In NASH, a ratio greater than 1 is a warning sign of potential severe scarring, even if your individual enzyme levels appear only mildly elevated. This marker helps identify who needs closer monitoring or biopsy.

SIRT1 regulates glucose homeostasis and insulin secretion by repressing UCP-2 in pancreatic beta-cells, thereby promoting efficient ATP production in response to glucose.

SIRT1 helps beta-cells secrete insulin efficiently by ensuring mitochondria produce ATP effectively. This mechanism is crucial for maintaining blood sugar levels, especially after meals.

FTO-mediated demethylation of N6-methyladenosine (m6A) on mRNA regulates alternative splicing of adipogenic factors (specifically RUNX1T1) and is required for adipogenesis.

This research explains the biological basis of fat cell formation. While you cannot directly control FTO or m6A levels with a simple supplement, understanding that fat cells must actively differentiate helps explain why weight loss is difficult once fat cells are established. Maintaining a healthy weight prevents the need for new fat cell formation.

Transplantation of brown adipose tissue (BAT) into the visceral cavity of mice improves glucose tolerance, insulin sensitivity, and reduces body weight and fat mass through an IL-6-dependent endocrine mechanism.

This study shows that increasing brown fat activity (via transplantation in mice) improves insulin sensitivity and reduces fat mass through the release of IL-6 and FGF21. While human transplantation is not a viable option, these findings suggest that strategies to activate brown fat—such as cold exposure or specific pharmacological agents targeting IL-6 or FGF21 pathways—might help combat obesity and type 2 diabetes by improving glucose metabolism.

Long-term consumption of a high-fat diet induces local proinflammatory signaling (TNF-alpha, IL-1beta, JNK, NF-kB) in the hypothalamus, which directly causes insulin resistance and impairs the brain's ability to regulate food intake and energy expenditure.

Eating a diet very high in fat can trigger inflammation in the brain's hunger-control center (hypothalamus). This inflammation blocks insulin's ability to tell your brain you are full, leading to overeating and weight gain. Reducing high-fat intake may help reduce this brain inflammation and restore normal hunger signals.

Pharmacological inhibition of the TORC1 branch of the TOR pathway using rapamycin extends the life span of adult Drosophila melanogaster.

This study confirms that inhibiting the TOR pathway via rapamycin extends life span in fruit flies. The mechanism involves specific downstream effects on autophagy and translation, not just reduced fertility or insulin signaling. While this is a model organism study, it supports the hypothesis that TOR inhibition is a conserved longevity mechanism.

Rapamycin extends life span in Drosophila specifically through the TORC1 branch by modulating autophagy and protein translation.

The longevity benefits of rapamycin in flies are driven by its ability to inhibit TORC1, which in turn increases autophagy (cellular cleanup) and reduces protein translation. This suggests that cellular maintenance and reduced growth signaling are key to longevity.

Rapamycin treatment increases resistance to oxidative stress (paraquat) and starvation in Drosophila.

Rapamycin treatment not only extends life but also improves the ability of flies to survive acute stressors like starvation and oxidative damage, suggesting improved physiological resilience.

Rapamycin extends life span beyond the maximum achieved by dietary restriction (DR) in Drosophila.

Rapamycin extends life span even when dietary restriction (a known longevity intervention) is already maximized, suggesting it works through mechanisms that DR does not fully capture.

In nonalcoholic steatohepatitis (NASH), the accumulation of triglyceride in lipid droplets is an innocent bystander and protective mechanism, whereas lipotoxicity is caused by nontriglyceride fatty acid metabolites (such as ceramides, diacylglycerols, and lysophosphatidylcholine) that induce cellular injury, inflammation, and apoptosis.

Focus on reducing the flow of fatty acids into the liver rather than just trying to 'detox' stored fat. This is achieved by improving insulin sensitivity (reducing inappropriate lipolysis from fat tissue) and limiting carbohydrate intake (reducing de novo lipogenesis). The presence of liver fat (steatosis) is not the primary enemy; the toxic metabolites generated from unmanaged fatty acid flux are.

Somatic mitochondrial DNA (mtDNA) mutations drive progeroid (premature aging) phenotypes in mammals primarily through the dysfunction of somatic stem cells, rather than through the accumulation of oxidative damage.

Focus on maintaining overall metabolic health and physical activity, which naturally supports mitochondrial function and stem cell health. Do not rely on antioxidant supplements to reverse aging, as evidence suggests they may be ineffective or harmful. The key takeaway is that cellular maintenance (like stem cell health) is more critical than simply neutralizing free radicals.